Skip to Main Content

Paper Details

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
J Clin Oncol
7
2023
Advanced Melanoma, PD-1, Patients, Programmed cell death 1, Tumor, activated T cells, advanced melanoma, cancer, melanoma, metastatic melanoma, nivolumab, patient, patients
Author NameAffiliation
Harriet M KlugerThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, Beth Israel Deaconess Medical Center Donald P. Lawrence, Massachusetts General Hospital Cancer Center F. Stephen Hodi, Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, Georgetown-Lombardi Comprehensive Cancer Center, Carolina BioOncology Institute, The Christ Hospital Cancer Center, Vanderbilt University Medical Center, University of Michigan ann arbor
Harriet M KlugerThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, Beth Israel Deaconess Medical Center Donald P. Lawrence, Massachusetts General Hospital Cancer Center F. Stephen Hodi, Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, Georgetown-Lombardi Comprehensive Cancer Center, Carolina BioOncology Institute, The Christ Hospital Cancer Center, Vanderbilt University Medical Center, University of Michigan ann arbor
David C SmithThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, Beth Israel Deaconess Medical Center Donald P. Lawrence, Massachusetts General Hospital Cancer Center F. Stephen Hodi, Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, Georgetown-Lombardi Comprehensive Cancer Center, Carolina BioOncology Institute, The Christ Hospital Cancer Center, Vanderbilt University Medical Center, University of Michigan ann arbor
  • 1 - 3

Datasets

Release 1.2